Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients.
Dracen Pharmaceuticals has raised $2.3M in total funding. The most recent round was Debt Financing. The last funding was announced in August 2023.
Dracen Pharmaceuticals's investors include OUP (Osage University Partners), Deerfield, i&i Prague.
Dracen Pharmaceuticals is headquartered in Baltimore, United States.
Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients.
Dracen Pharmaceuticals is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Dracen Pharmaceuticals — Funding & Investors." VCBacked, August 10, 2023, https://www.vcbacked.co/company/dracen-pharmaceuticals. Accessed August 14, 2026.
VCBacked. (2023). Dracen Pharmaceuticals — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/dracen-pharmaceuticals
{{cite web |title=Dracen Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/dracen-pharmaceuticals |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated